Mar
31

Can anyone with MS recommend a course of treatment?

Posted by admin Comments (1)

Question by KTry: Can anyone with MS recommend a course of treatment?
I was just diagnosed with MS. I’ve done a ton of research, but I was wondering if anyone with MS can give me some insight as to what type of medication they are taking … pros & cons. Any help is greatly appreciated. Thanks!

Best answer:

Answer by robert b
My aunt has Multiple Sclerosis, i just called her up and she said she uses something called Avonex .

Avonex Indications –

Avonex is primarily used in the treatment of relapsing multiple sclerosis. It slows down the development of physical disability and decreases the frequency of exacerbation. It may also be used for purposes other than those mentioned here.

Give your answer to this question below!

Mar
30

Multiple Sclerosis Awareness Bracelet, Yellow- Survivor/Patient

Posted by admin Comments (0)

Multiple Sclerosis Awareness Bracelet, Yellow- Survivor/Patient

  • swarovski crystals
  • bali sterling silver
  • special color meaning card

The Colors of Hope Multiple Sclerosis bracelet comes in the nationally adopted awareness colors of red and gray. Created with swarovski crystals and bali sterling silver, this bracelet helps spread multiple sclerosis awareness and show support to those af

List Price: $ 65.00

Price: [wpramaprice asin="B000P4BAVE"]

Mar
30

Pipeline Insight: Inflammatory Bowel Disease – Varied drug targets to broaden future therapy options now available at ReportsandReports

Posted by admin Comments (0)

Datamonitor forecasts the inflammatory bowel disease market to become increasingly competitive with the anticipated launch of seven new products, spanning five drug classes from 2010 to 2019. These therapies are forecast to inject over billion into a market projected to reach up to .7 billion by 2019 and offer more therapy choice to specific patient groups.

Scope

*Segmentation and analysis of products across all stages of the IBD pipeline with in-depth discussion of key Phase II and III pipeline therapies

*Insight and analysis of market potential including robust epidemiology forecasts, and a review of key opinion leader requirements for new products

*Ten-year indication-specific forecasts of seven pipeline products, with a comparison of their relative clinical and commercial attractiveness

*Review of unmet needs based on key opinion leader interviews and a focus on innovative early-stage drug development and assessment of future treatment

Highlights

Datamonitor identified 108 products across all stages of development, but these treatments vary immensely by target. The diversity of the pipeline will broaden future therapy choice for specific patient groups, such as TNF-failure patients and the mild to moderate group.

Opinion leaders cite the re-randomization of patients responding to initial treatment in Crohn’s disease trials as an effective design. In ulcerative colitis assessing induction and maintenance treatment in separate studies of new drugs will play a significant role in drug labeling, particularly for the European Medicines Agency.

Two key late-stage pipeline drugs show particular clinical and commercial potential. Simponi (golimumab) is viewed positively by opinion leaders for ulcerative colitis. In Crohn’s disease, chemokine antagonist GSK1605786 (Traficet-EN) is anticipated to reach the market by 2017 and could potentially threaten biologics as a maintenance agent.

Reasons to Purchase

*Understand the recent advances in the inflammatory bowel disease pipeline and gain insight into leading gastroenterologist opinion

*Access sales forecasts for late-stage pipeline products and understand new product positioning through analysis of clinical and commercial factors

*Evaluate the unmet needs in both Crohn’s disease and ulcerative colitis and the challenges faced in clinical trial development

Overview 1

Catalyst 1

Summary 1

About Datamonitor Healthcare 2

About the Immunology & Inflammation pharmaceutical analysis team 2

Executive Summary 3

Strategic scoping and focus 3

Datamonitor insight into the disease market 3

Related reports 5

Upcoming related reports 5

Table of Contents 6

1. Pipeline Overview and Dynamics 7

Key findings 7

Pipeline overview 8

Diverse late-stage pipeline for inflammatory bowel disease 8

Companies remain interested in inflammatory bowel disease, particularly ulcerative colitis 10

Limited number of candidates have made it to Phase III 11

Interleukin and TNF inhibitors are most commonly targeted, while development focuses on oral delivery 12

Comparative forecasts 14

Datamonitor pipeline assessment summary 16

Key companies involved in the inflammatory bowel disease pipeline 17

Centocor Ortho Biotech 17

Cosmo Pharmaceuticals 18

GlaxoSmithKline 18

2. Epidemiology 20

Key findings 20

Definition 21

Crohn’s disease 21

Ulcerative colitis 21

ICD-10 codes used to define the inflammatory bowel disease indications 21

Patient segmentation by anatomical location 22

Ulcerative colitis 23

Crohn’s disease 23

Patient segmentation according to disease severity 25

Crohn’s disease 25

Mild-to-moderate Crohn’s disease 25

Moderate-to-severe Crohn’s disease 25

Fistulizing Crohn’s disease 25

Severe fulminant Crohn’s disease 26

Remission in Crohn’s disease 26

Ulcerative colitis 26

Mild ulcerative colitis 26

Moderate ulcerative colitis 26

Severe ulcerative colitis 26

Fulminant ulcerative colitis 27

Remission 27

Segmentation of patients by severity useful for directing therapy, but is not clearcut 28

Disease definition and diagnosis criteria used in epidemiology analysis 28

Crohn’s disease 29

Ulcerative colitis 29

Global variation and historical trends 30

Risk factors 33

Genetics 33

Environmental factors 34

Smoking 34

Epidemiologic forecasting of IBD 35

Sources of epidemiologic data 35

Description of methods 35

Japan 36

US 36

European markets 36

Epidemiological results 38

Current prevalent cases and future trends of Crohn’s disease 38

Current prevalent cases and future trends of ulcerative colitis 41

Discussion 44

Strengths of Datamonitor’s epidemiologic projections 45

Conclusions 45

Rest of the world 46

3. Current Market Overview 47

Key Findings 47

Current treatment options 48

Topical and oral 5-aminosalicylates (5-ASAs) 48

Corticosteroids 49

Immunomodulators 49

Biologics 50

Antibiotics 50

Antidiarrheal and fluid replacement 50

Leading treatments for inflammatory bowel disease 50

Current gold standard and comparator therapies 52

5-aminosalicylates remain the gold-standard therapy in ulcerative colitis 52

Gold-standard in Crohn’s disease is less clearcut 53

Comparator drug 54

Remicade (infliximab) is the comparator therapy in both Crohn’s disease and ulcerative colitis 54

Current market overview 55

Unmet needs in Crohn’s disease and ulcerative colitis 58

Crohn’s disease 58

Effective agents for maintaining remission without immunosuppression 58

Drugs needed for mild Crohn’s disease population 59

Safer oral therapies as an alternative to expensive biologics 59

Effective treatments for fistulizing Crohn’s disease 59

Predicting response to therapy 60

Better activity measurements in clinical trials 60

Ulcerative colitis 61

Powerful, well-tolerated agents for inducing remission quickly and an oral maintenance agent are most wanted 61

Drug therapies for refractory patient population 61

Disease-modifying drugs 62

Simple blood test to indicate disease activity 62

Target product profile versus current level of attainment 62

Efficacy 64

Crohn’s disease 64

Ulcerative colitis 65

Safety 66

Formulation 66

Cost 67

4. R&D Approach 68

Key findings 68

Clinical trial design in Crohn’s disease 69

Changes in inflammatory bowel disease clinical trial design have been two-fold over the last decade 69

Crohn’s disease trial design remains a work in progress, but aided by several recently published guidelines 70

Indices that reflect inflammation are needed in modern Crohn’s disease trial design 72

Time point to assess the effectiveness of drugs in clinical trials 72

Randomization of patients from onset of trial with induction and maintenance endpoint deemed less effective 73

ACT, PRECiSE-2 and CHARM trials set a precedent for modern Phase III Crohn’s disease trials 74

Clinical trial design in ulcerative colitis 75

Ulcerative colitis clinical development guidelines for European approval 75

Indices in clinical trials of ulcerative colitis 76

Remicade’s ACT clinical trial set the precedent for modern ulcerative colitis trial design 76

5. Pipeline Analysis & Forecasts: TNF inhibitors 78

Key findings 78

Overview for TNF inhibitors 79

Pipeline summary 79

Simponi (golimumab; Centocor Ortho Biotech/Merck & Co./Mitsubishi Tanabe) 79

Drug overview 79

Drug profile 80

Clinical trial data 80

SWOT analysis 82

Datamonitor drug assessment summary for Simponi 83

Clinical and commercial attractiveness 85

Potential to switch patients from Remicade to Simponi 85

Simponi targets only the moderate to severe ulcerative colitis subgroup 87

Company experience boosts commercial attractiveness, but arbitration between Johnson & Johnson and Schering-Plough is concerning 87

Satisfaction of unmet needs 87

Forecasts to 2019 89

TNF-kinoid (debio0512; Neovacs) 91

Key early-stage and preclinical compounds in TNF inhibitors 91

6. Pipeline Analysis & Forecasts: Corticosteroids 93

Key findings 93

Overview for corticosteroids 94

Pipeline summary 94

Budesonide MMX (Cosmo/Ferring/Santarus) 94

Drug overview 94

Drug profile 95

Clinical trial data 95

Phase III studies 95

SWOT analysis 98

Datamonitor drug assessment summary for Budesonide MMX 99

Clinical and commercial attractiveness 101

MMX delivery system sets Budesonide MMX apart from other corticosteroids 101

Potential for Budesonide MMX as first-line ulcerative colitis therapy, but more data needed 103

Commercial potential for Budesonide MMX in the European market 103

Satisfaction of unmet needs 104

Forecasts to 2019 105

Other drugs in the corticosteroid class 108

COLAL-PRED (prednisolone sodium metasulfobenzoate) 108

Key preclinical compound in corticosteroids 110

7. Pipeline Analysis & Forecasts: Integrin inhibitors 111

Key findings 111

Overview for integrin inhibitors 112

Pipeline summary 112

Comparative forecasts 112

Vedolizumab (MLN0002; (Takeda/Millennium Pharmaceuticals) 114

Drug overview 114

Drug profile 114

Clinical trial data 115

Phase III studies: GEMINI studies 115

SWOT analysis 118

Datamonitor drug assessment summary for vedolizumab 118

Clinical and commercial attractiveness 120

Targeting both Crohn’s disease and ulcerative colitis boosts patient potential 120

Safety profile negatively impacts on clinical attractiveness 122

Takeda has available resources, but lacks experience in inflammatory bowel disease 122

Satisfaction of unmet needs 122

Forecasts to 2019 125

AJM300 (Ajinomoto) 128

Drug overview 128

Drug profile 128

Clinical trial data 128

SWOT analysis 130

Datamonitor drug assessment summary for AJM300 130

Clinical and commercial attractiveness 132

Large patient potential as both Crohn’s disease and ulcerative colitis are targeted 132

Ajinomoto gaining inflammatory bowel disease market experience 134

Satisfaction of unmet needs 134

Forecasts to 2019 136

Key early-stage and preclinical compounds in integrin inhibitors 138

8. Pipeline Analysis & Forecasts: Other cytokine targets 139

Key findings 139

Overview for cytokine targets 140

Pipeline summary 140

Comparative forecasts 140

Stelara (ustekinumab; Centocor Ortho Biotech/Janssen-Cilag) 142

Drug overview 142

Drug profile 142

Clinical trial data 143

SWOT analysis 145

Datamonitor drug assessment summary for Stelara (ustekinumab) 146

Clinical and commercial attractiveness 148

Formulation strategy remains unclear 148

Potential for ustekinumab in anti-TNF failure or biologics setting 149

Company experience in the autoimmune area 149

Satisfaction of unmet needs 150

Forecasts to 2019 151

GSK1605786 (formerly Traficet-EN, CCX282; ChemoCentryx/GlaxoSmithKline) 153

Drug overview 153

Drug profile 154

Clinical data 154

PROTECT-1: maintenance phase of trial shows positive data 155

PROTECT-1: induction phase of study 157

Phase II trial data 159

SWOT analysis 159

Datamonitor drug assessment summary for GSK1605786 (Traficet-EN) 160

Clinical and commercial attractiveness 162

Positive Phase II/III shows more definitive data on remission but dosing issues need to be resolved 162

Commercial potential boosted by GlaxoSmithKline’s resources, but the company lacks IBD experience 164

First-in-class for Crohn’s disease as an alternative to immunosuppressants 164

ChemoCentryx is also developing CCX025, a potential back-up to GSK1605786 164

Potential for future indication expansion into ulcerative colitis 164

Satisfaction of unmet needs 164

Forecasts to 2019 165

ABT-874 (briakinumab; Abbott) 167

AIN457 (Novartis) 169

AG011 (ActoGeniX) 169

STA5326 (apilimod mesylate; Synta Pharmaceuticals) 170

MDX-1100 (Bristol Myers Squibb) 170

Late-stage development compounds recently discontinued 171

Simulect (Basiliximab BSX; Cerimon Pharmaceuticals) 171

Rebif (interferon-beta-1a; Merck Serono) 171

Key early-stage and preclinical compounds in other cytokine targets 172

9. Pipeline Analysis & Forecasts: Others 173

Key findings 173

Overview for other drugs 173

Pipeline summary 173

LMW Heparin MMX (CB-01-05-MMX, parnaparin sodium; Cosmo Pharmaceuticals) 175

Drug overview 175

Drug profile 176

Clinical trial data 176

SWOT analysis 178

Datamonitor drug assessment summary for LMW Heparin MMX 179

Clinical and commercial attractiveness 181

Large patient potential as LMW Heparin MMX targets mild-to-moderate ulcerative colitis 181

Cosmo has some market experience in ulcerative colitis 182

Promising initial clinical data support clinical attractiveness 182

Satisfaction of unmet needs 182

Forecasts to 2019 184

Prochymal (Osiris Therapeutics/Genzyme) 185

Drug overview 185

Drug profile 186

Clinical trial data 186

Phase III Crohn’s disease study enrollment discontinued, but strong partnership with Genzyme 188

Alicaforsen sodium (AP1431, AP1451, AP1007; Atlantic Healthcare) 189

Drug overview 189

Clinical data 190

Other drugs 190

Tasocitinib (CP-690550; Pfizer) 190

Tetomilast (OPC6535; Otsuka Pharmaceuticals) 193

LT-02 (Lipid Therapeutics) 194

HMPL004 (Hutchison MediPharma) 195

Dersalazine sodium (UR-12715; Palau Pharma) 196

Late-stage development compounds recently discontinued 196

Orencia (abatacept; Bristol-Myers Squibb) 196

Drug overview 196

Drug profile 197

Clinical trial data 197

Phase III Crohn’s disease study 197

Phase III ulcerative colitis study 200

Clinical program of abatacept for inflammatory bowel disease comes to an end 202

Visilizumab (HuM291; PDL BioPharma) 202

Key early-stage compounds in others 203

10. Innovative Early-Stage Approaches 206

Key findings 206

Overview of early-stage innovative projects 207

Toll-like receptors- promising preclinical target 207

Interleukin 6 – preclinical models suggest potential in inflammatory bowel disease 208

Targeting IL-6 five or more years away in inflammatory bowel disease 210

Interleukin 10 -potential target for inflammatory bowel disease 211

Early-stage inflammatory bowel disease pipeline is diverse 211

The future of treatment in inflammatory bowel disease 211

Bibliography 214

Journals 214

Websites 224

Datamonitor reports 230

APPENDIX 231

Methodology 231

Datamonitor forecast methodology 231

Product forecasts 231

Derivation of sales forecasts and pricing trends 231

Exchange rates 231

Definition of a standard unit 232

Datamonitor drug assessment scorecard 232

Contributing experts 233

About Datamonitor 234

About Datamonitor Healthcare 234

About the Disease analysis team 234

Datamonitor consulting 235

Disclaimer 237

ReportsandReports, comprising of an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. ReportsandReports announce to have Research Report on Pipeline Insight: Inflammatory Bowel Disease – Varied drug targets to broaden future therapy options Market Research Report in its store. Browse all our Market Research Reports details at ReportsandReports.com


Article from articlesbase.com

Unfortunately the video is me when I was first diagnosed at age 15, I am now 46 years of age. Looking back at this video I cannot believe how frightened that young girl was and it’s hard for me to watch even to this day. Guess what? Not only do I have Parkinson’s Disease, I also have MS. I can’t understand what is up with this? I guess it could be worse. I’m not here to whine or complain and I most definately DO NOT want ANYONE feeling sorry for me. I am here because I feel and have felt it is long past time the government and pharmaceutical houses do something productive besides managing to get away with distributing drugs that are not (in my opinion) suitable to be distributed to those who suffer day in and day out with this illness. It is a most unforgiving illness and the medicines are archaic. If you or a loved one has PD I can recommend a wonderful hospital with doctors who surpassed all my expectations (and I have seen too many neurologists to list). Contact me if you would like the information. You may reach me at: tlrothwell@gmail.com or you can google Tammy Rothwell. Look, anyone living in communities that have any type of insecticides spred in their air that might eventually enter the water table is vulnerable. If you carry the PD gene, it is a very good possibility you could pass that on to your child, or even (which might be the case with me) is a dormant gene from a virus from many years ago quite similar to the H1 virus of today. Scary? You’re darned right
Video Rating: 0 / 5

Find More Ms Disease Articles

Mar
29

How do I promote my cause?

Posted by admin Comments (1)

Question by Mike: How do I promote my cause?
I am building my resume for college and for many years now I have been dedicated to helping the fight against Multiple Sclerosis. So I volunteered to be a promoter for the National MS Society’s various fund raising events. I have posters, pamphlets, and trading cards by the hundreds. My question- where do I start?

Can I just go to Dick’s Sporting Goods and introduce myself to the manager and ask if I could place them in the checkout lines?
Other places I could go??

Best answer:

Answer by Jason Brown
Alot of people would be willing to buy shirts to help promote and raise money. use vistaprint-

use this link to get a big percentage off your first purchase

http://vistaprint.tellapal.com/a/clk/Bln90

Add your own answer in the comments!

Mar
28

Latest National Ms Society auctions

Posted by admin Comments (0)

Some recent national ms society auctions on eBay:

[wprebay kw="national+ms+society" num="0" ebcat="-1"]
[wprebay kw="national+ms+society" num="1" ebcat="-1"]
[wprebay kw="national+ms+society" num="2" ebcat="-1"]

Mar
27

Symptom Management in Multiple Sclerosis

Posted by admin Comments (3)

Symptom Management in Multiple Sclerosis

Concise text for multiple sclerosis patients and their families on living with the disease. Topics include: fatigue, spasticity, weakness, tremor, sexuality, bladder and bowel symptoms, pain, and speech difficulties. Previous edition: c1994. Softcover. DNLM: Multiple Sclerosis–therapy.

List Price: $ 19.95

Price: [wpramaprice asin="1888799226"]

Find More Symptoms Of Multiple Sclerosis Products

Mar
26

Multiple Sclerosis ? Causes, Symptoms and Types

Posted by admin Comments (0)

Multiple sclerosis is a disease that may affect any area of the brain and spinal cord. Multiple sclerosis does not affect nerve cells. Multiple sclerosis affects transmission of electrical signals to nerve cells. Multiple sclerosis is the most common cause of chronic neurological disability in young adults. Multiple sclerosis is not contagious.

This is seen most clearly in the physical demyelination of nerve membranes and the many symptoms of decreased nervous system function that accompany MS. According to Ayurveda theory, the functioning mode in the body called Vata controls the overall level of balance and activation of the nervous system. MS is a classic Vata imbalance from this perspective.

Causes

Multiple sclerosis is an autoimmune disease, meaning its cause is an attack by the body’s own immune system. For unknown reasons, immune cells attack and destroy the myelin sheath that insulates neurons in the brain and spinal cord. This myelin sheath, created by other brain cells called glia, speeds transmission and prevents electrical activity in one cell from short-circuiting to another cell. Disruption of communication between the brain and other parts of the body prevent normal passage of sensations and control messages, leading to the symptoms of MS. The demyelinated areas appear as plaques, small round areas of gray neuron without the white myelin covering.

Symptoms

Symptoms of multiple sclerosis may be single or multiple and may range from mild to severe in intensity and short to long in duration. Complete or partial remission from symptoms occurs early in about 70% of multiple sclerosis patients.

Visual disturbances may be the first symptoms of multiple sclerosis, but they usually subside. A patient may notice blurred vision, red-green distortion (color desaturation), or sudden monocular blindness (blindness in one eye). Muscle weakness with or without difficulties with coordination and balance may occur early. Muscle spasms, fatigue, numbness, and prickling pain are common symptoms.

Diet

As the diet may contain high levels of polyunsaturates, a good intake of vitamin E, vitamin B6, zinc and vitamin C is needed. Vitamin E is the main antioxidant that helps prevent peroxidation of polyunsaturates and vitamin C helps to protect vitamin E. Zinc and vitamin B6 are part of the enzyme delta-6-desaturase which is involved in conversion of linoleic acid (found in polyunsaturated fat and oils) to its longer chain derivatives.

Types of MS

There are four types of MS and each progresses differently.

Benign MS

With this type you will have a few relapses (times when your symptoms flare up) and then recover. However, you need to have had very few or no symptoms for about 15 years before this diagnosis can be made.

Secondary progressive

Secondary progressive describes around 80% of those with initial relapsing – remitting MS,who then begin to have neurologic decline between their acute attacks without any definite periods of remission. This decline may include new neurologic symptoms , worsening cognitive function, or other deficits. Secondary progressive is the most common type of MS and causes the greatest amount of disability.

Relapsing-remitting MS

For about 80 percent of people with MS, it begins as a relapsing and remitting condition. This means you have relapses followed by periods of remission when your symptoms get better.

Find More Multiple Sclerosis Early Symptoms Articles

Mar
26

Secondary Causes of Fatigue in MS – National MS Society

Posted by admin Comments (1)

MS Learn Online is the National MS Society’s online educational webcast series. This video features a discussion about the possible secondary causes of fatigue for people with multiple sclerosis.
Video Rating: 0 / 5

MS Learn Online is the National MS Society’s online educational webcast series. This video features Mary Hughes, MD, who answers a viewer’s question about what causes depression in multiple sclerosis.
Video Rating: 5 / 5

Mar
25

Information about Multiple Sclerosis (MS)

Posted by admin Comments (18)

articles.mercola.com Internationally renowned natural health physician and Mercola.com founder Dr. Joseph Mercola talks about Multiple Sclerosis or MS.
Video Rating: 4 / 5

Sarah Keitt explains what causes her sensitivity to heat. For more information on multiple sclerosis visit www.empowher.com
Video Rating: 0 / 5

Mar
24

Multiple Sclerosis News

Posted by admin Comments (0)

Multiple sclerosis disrupts the flow of information at intervals the brain and so the flow of knowledge to the rest of the body. Multiple Sclerosis will cause tremors, numbness, concentration problems, slurred speech, coordination issues, blurred vision (even blindness), paralysis, loss of balance and more.

There’s no known cure for MS; so it’s thought-about a chronic health disease. Though there’s no cure there have been positive advancements and accomplishments in analysis in addition to legislation and support for people who have the disease.The National MS Society is one of the foremost well-known organizations related to MS research, news, fundraising and overall advocacy. Quality healthcare is an ongoing concern for people with MS and cheap health insurance is one of the many priorities for the Society. Among the numerous topics that the Society advocates is eliminating the 24 month waiting period for Medicare incapacity (currently, people who’s MS is thus severe that they can not work and would ultimately be eligible for Social Security Disability edges must wait for 24 months before Medicare will give healthcare coverage) and access to lifesaving medication (urging of Congress to produce pathways for the FDA to approve safe lower value biological drugs).The National MS Society’s advocacy efforts resulted in several legislation successes in 2009 like family caregiver outreach, family caregiver support and Health Insurance Risk Pool Premium Discounts (typical premiums for Health Insurance Risk Pool have been known to be double the amount on commonplace premiums).

The Health Insurance Risk Pool is one in every of the few insurance choices for individuals with MS, as it is considered a chronic illness. So, discounted premiums would be thought of a large success.The National MS Society is steadfast in its focus to provide programs and services to all or any individuals who are stricken by MS along with awareness to those that may need detailed info or resources concerning the disease. The Society raises awareness through events like the annual Bike MS and Walk MS events also Women on the Move Luncheons to name a few. In 2009, the Society held one hundred Bike MS rides and 600 Walk MS events throughout the United States. The result: millions of individuals coming back together to raise uncountable bucks to support those living with the daily challenge of MS. The events have proven to be useful financially in addition to providing a festive atmosphere for attendees and participants.There are more than 2.5 million individuals in the world and 400,000 individuals within the United States full of MS. The National Multiple Sclerosis Society seeks to achieve a world free of MS through fundraising and awareness events. For more data concerning MS research, awareness or Society events visit the Texas low value health insurance site and search MS resources.

Martin has been writing articles online for nearly 2 years now. Not only does this author specialize in Diseases Multiple Sclerosis , you can also check out his latest website about:
Kids Skate Shoes Which reviews and lists the bestKids Adio Skate Shoes


Article from articlesbase.com

Find More National Multiple Sclerosis Society Articles